Autopsy report · NCT06162299

A Phase I, the Study to Evaluate the Safety, Immunogenicity and Efficacy of YS-HBV-002

“Business strategy”

The sponsor’s own words in the registry.

Life of this trial

• Registered 7 months before it started.
• Ran for about 4 months before it stopped.
• 16 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Yisheng Biopharma (Singapore) Pte. Ltd.

Sponsor type

Industry

Conditions

Chronic Hepatitis B

Interventions

YS-HBV-002

Participants

16

Sites

1

Countries

Philippines

Trials that died the same way

• Automated Breast Ultrasound Case Collection Registry
  “Change in business strategy” (86% match in meaning)
• ARX788 in Selected HER2-mutated or HER2-amplified/Overexpressed Solid Tumors (ACE-Pan Tumor-02)
  “Business strategy change” (85% match in meaning)
• Dose-escalation Study of APG-1387 and Toripalimab in Solid Tumors
  “Company Strategy” (85% match in meaning)
• Rapid Amniotic Fluid (AF) Test and a Non-Invasive Vaginal Fluid (VF) Test
  “Business Strategic Decision” (79% match in meaning)
• Clinical and Microbial Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% in the Treatment of Bacterial Conjunctivitis
  “Strategic business decision” (78% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.